GoodRx Holdings
GDRX
167 hedge funds and large institutions have $2.79B invested in GoodRx Holdings in 2022 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 55 increasing their positions, 45 reducing their positions, and 77 closing their positions.
27% more call options, than puts
Call options by funds: $48.6M | Put options by funds: $38.2M
22% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 45
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
21.7% less ownership
Funds ownership: 189.31% → 167.61% (-22%)
23% less funds holding
Funds holding: 216 → 167 (-49)
44% less capital invested
Capital invested by funds: $4.99B → $2.79B (-$2.2B)
60% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 77
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$130M |
| 2 |
LSCM
Light Street Capital Management
Palo Alto,
California
|
+$63.9M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$56.9M |
| 4 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$25M |
| 5 |
DM
Deerfield Management
New York
|
+$22.5M |
Top Sellers
GDRX Hedge Fund Activity: Q1 2022 in Review
167 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in GoodRx Holdings (GDRX) for Q1 2022, worth a combined $2.79B — down 44% from $4.99B a quarter earlier.
Sellers outnumbered buyers: 77 funds closed out of GDRX and 31 opened new positions — a net loss of 46 holders — while 45 trimmed existing stakes and 55 added.
The largest buyer was Morgan Stanley, adding an estimated $130M. The largest seller was Abdiel Capital Advisors, exiting entirely with an estimated $263M sold.
- 167 institutional investors held GoodRx Holdings (GDRX) as of Q1 2022, down from 216 in Q4 2021.
- Funds reported $2.79B of GoodRx Holdings stock for Q1 2022, down 44% quarter-over-quarter.
- 31 funds opened new GoodRx Holdings positions in Q1 2022 and 77 closed out, a net change of -46 holders.
- The largest GoodRx Holdings buyer in Q1 2022 was Morgan Stanley, an estimated $130M added.
- The largest GoodRx Holdings seller in Q1 2022 was Abdiel Capital Advisors, an estimated $263M sold.
Based on aggregated 13F filings for Q1 2022.